Dr. Loic Lang-Lazdunski
Surgical Oncologist & Contributing WriterDr. Loic Lang-Lazdunski joined the Quebec Heart and Lung Institute at Laval University in 2020 after almost two decades in the United Kingdom, where he built his reputation as one of Europe’s foremost authorities on pleural mesothelioma surgery.
Last modified: September 29, 2021
-
Expertise:Pleural Mesothelioma
Mesothelioma Surgery
Research
-
Certifications:Xavier Bichat Medical School, Paris, France
Post-Doctoral Research Fellow, Harvard Medical School -
Memberships:European Association for Cardio-Thoracic Surgery
European Society of Thoracic Surgeons
International Mesothelioma Interest Group
International Association for the Study of Lung Cancer
About Dr. Lang-Lazdunski
Although he is recognized as one of the world’s foremost authorities on mesothelioma surgery, Dr. Loic Lang-Lazdunski believes it takes a specialty center with multidisciplinary expertise to treat the cancer optimally.
“It’s the collaboration with experts in all the fields that will make us successful with these patients,” he said. “It’s the personalization of the treatment and the extensive experience from pulmonologists, surgeons, oncologists, pathologists, anesthetists and nurses on staff.”
Lang-Lazdunski came to Quebec after 12 years as a consultant thoracic surgeon at Guy’s and St. Thomas’ NHS Foundation Trust in London. He became professor of thoracic surgery at King’s College, London, with a chair in mesothelioma in 2012.
His extensive experience in treating pleural mesothelioma — and his success — has led to an international following. He contributes regularly to the European Lung Cancer Congress, World Conference on Lung Cancer, International Mesothelioma Interest Group, American Society of Clinical Oncology, the European Society of Thoracic Surgeons and The Mesothelioma Center at Asbestos.com, the nation’s most trusted mesothelioma resource.
Lang-Lazdunski collaborates with prominent specialists worldwide and has contributed several landmark studies that have helped improve both treatment and prognosis of pleural mesothelioma.
